What's New on the FDA Drugs Site
August 4, 2017
- CDER Statement: FDA warns consumers not to use Balguti Kesaria Ayurvedic Medicine due to high levels of lead
- Compounding Risk Alerts
- An FDA Investigation into Two Serious Adverse Events Associated with ImprimisRx’s Compounded Curcumin Emulsion Product for Injection
- Product-Specific Guidances for Generic Drug Development (updated) 48 Finalized Guidances
- Drug Trial Snapshot: Tremfya
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- FDA Drug Shortages
- Rocuronium Bromide Injection (Updated - Currently in Shortage)
- Scopolamine (Transderm Scop) Transdermal System Patch (Updated - Currently in Shortage)
- National Drug Code Directory
- Wholesale Distributor and Third-Party Logistics Providers Reporting (updated)
- Medication Guides Page (Updated)
No hay comentarios:
Publicar un comentario